TEST:

Neo Comprehensive - Solid Tumor Assay

The study concluded that for Neo Comprehensive solid tumor genome profiling NGS panel, where accuracy and consistency in data quality are crucial, qPCR-based quantification is the standard method. Nevertheless, fluorescence-based quantification using the Tecan Qubit system has shown comparable results and remains a viable option for the final library quantification which offers significant time savings and lower costs. It can result in variable cluster density and sequencing performance.

The Neo ComprehensiveTM Solid Tumor pan cancer assay enabled simultaneously analysis of both DNA and RNA in one integrated workflow with an accompanying DragenTM bioinformatics analysis platform and provided comprehensive genomic profiling of sequence and structural variants, as well as genomic signatures such as TMB and MSI in OSCC patients. Utility of the NanoString PCIP highlighted immune-relevant gene expression changes within the different sample cohorts. The detailed molecular information highlighted by our study emphasizes the need for improved patient classification based on smoking status in the management of OSCC and also in establishing potential therapeutic options based on the many altered cell signaling pathways that we identified.

Precision medicine has become increasingly important for management of cancer patients including comprehensive genomic profiling (CGP) and molecular residual disease (MRD). Join us to learn more about NeoGenomics suite of advanced sequencing tests.NeoComprehensive™ – Solid Tumor and NeoComprehensive™ – Myeloid leverage both DNA and RNA sequencing analysis to detect multiple classes of genomic alterations that are relevant for diagnosis, therapy selection, prognosis, and clinical trials.RaDaR® is a personalized liquid biopsy test for the detection of MRD and recurrence, detecting the trace amounts of ctDNA that remain after surgery or other curative intent treatment, and early signs of relapse.

"NeoGenomics, Inc...announced today the expansion of their next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of multiple tests, including Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor cancers, and Neo Comprehensive - Myeloid Disorders, a CGP for myeloid neoplasms."